A 26-year-old female with pre-B acute lymphocytic leukaemia was admitted to our hospital on November 18, 2009 for re-induction chemotherapy. She was started on high-dose cytarabine, L-asparaginase, acyclovir and trimethoprim-sulphamethoxazole. On admission, her absolute neutrophil count (ANC) was 800 cells/lL. On hospital day 3, she developed a nonproductive cough and had a temperature of 102.6°F with an ANC of 300 cells/lL. She was started on vancomycin, cefepime and oseltamivir 75 mg twice daily. One of two blood cultures grew a-haemolytic streptococci. A nasopharyngeal swab sent for respiratory viral panel testing (xTAG Ò RVP; Luminex Corp., Austin, TX, USA) revealed influenza A (H1N1), nonsubtypeable probable swine-origin and rhinovirus (Table 1) . On hospital day 8, she had a temperature of 103.6°F and posaconazole and meropenem were added, oseltamivir was continued, and cefepime was stopped. Chest computed tomography (CT) demonstrated patchy airspace disease in the right lung consistent with pneumonia. Fevers continued and several blood and urine cultures were negative. A bronchoscopy performed on hospital day 11 revealed negative cultures for aerobic, anaerobic, and acid-fast After her death, we performed resistance testing on a stored sample of the initial influenza strain isolated on hospital day 3, which was sensitive to oseltamivir. Additional testing was also performed on the bronchoscopy specimen from hospital day 11, which demonstrated that resistance to oseltamivir had developed after 8 days of oseltamivir therapy. To our knowledge, this is the first case of oseltamivirresistant, swine-origin influenza A (H1N1) associated with a fatal outcome. Despite widespread use of oseltamivir for prophylaxis and treatment during the 2009-2010 influenza season, resistance to this agent is relatively rare [1] [2] [3] [4] [5] [6] [7] . In the USA, 42 of 52 individuals with resistance had documented exposure to oseltamivir (http://www.cdc.gov/flu/ weekly/; accessed 1 February 2009), suggesting that most cases of resistance in the USA developed under selective pressure to the drug. Resistance developed during oseltamivir treatment in our patient who was receiving 75 mg twice daily. The recent literature suggests that an increased dose of 150 mg twice daily may be preferable for critically ill patients [8] . The most commonly reported mutation associated with oseltamivir-resistant H1N1 swine-origin is the H275Y mutation [9] [10] [11] [12] . Resistance may develop more commonly in immunocompromised patients [6] , particularly those with haematological malignancies [2, 13] . Mortality from seasonal influenza in immunocompromised patients is high [12] . However, we are unaware of reported cases involving oseltamivir-resistant, H1N1 swine-origin associated with death, including immunocompromised patients. Resistance testing should be carried out in H1N1 swine-origin infected, immunocompromised patients who fail to respond appropriately to antiviral therapy. Higher dosing of oseltamivir at 150mg twice a day should also be considered in these patients.
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